Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Pantano

Showing results (61-70 of 130) with videos related to

Pageof 13
Sort By:
Critical Reviews in Oncology/Hematology|June 14, 2015
Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trialsMatteo Santoni, Alessandro Conti, Kalliopi Andrikou, et al.
Journal of Translational Medicine|January 17, 2026
Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non-small cell lung cancerSilvia Cavaliere, Marta Fogolari, Michele Iuliani, et al.
British Journal of Cancer|July 13, 2023
MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemnessMargherita Puppo, Manoj Kumar Valluru, Martine Croset, et al.
Chemotherapy|June 10, 2024
Concurrent Use of Abemaciclib and Radiotherapy in Metastatic Breast Cancer Patients: A Single-Center ExperienceEdy Ippolito, Francesco Pantano, Sonia Silipigni, et al.
Expert Opinion on Biological Therapy|August 25, 2020
Denosumab for cancer-related bone lossEmanuela Dell'Aquila, Grazia Armento, Michele Iuliani, et al.
Critical Reviews in Oncology/Hematology|August 5, 2019
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trialsDaniele Santini, Antonio Galvano, Francesco Pantano, et al.
Cancer Biology & Therapy|June 14, 2013
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatmentFrancesco Pantano, Francesco Maria Guida, Caterina Vivaldi, et al.
Tumori|November 6, 2020
Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinomaRaffaele Ratta, Elena Verzoni, Alessia Mennitto, et al.
Hormones (Athens, Greece)|August 8, 2018
A novel germline mutation at exon 10 of MEN1 gene: a clinical survey and positive genotype-phenotype analysis of a MEN1 Italian family, including monozygotic twinsAndrea Palermo, Ettore Capoluongo, Rossella Del Toro, et al.
International Journal of Molecular Sciences|August 12, 2023
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate CancerMaria Concetta Cursano, Emilio Francesco Giunta, Emanuela Scarpi, et al.
Pageof 13

Showing results (61-70 of 130) with videos related to

Sort By:
Pageof 13
Critical Reviews in Oncology/Hematology|June 14, 2015
Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trialsMatteo Santoni, Alessandro Conti, Kalliopi Andrikou, et al.
Journal of Translational Medicine|January 17, 2026
Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non-small cell lung cancerSilvia Cavaliere, Marta Fogolari, Michele Iuliani, et al.
British Journal of Cancer|July 13, 2023
MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemnessMargherita Puppo, Manoj Kumar Valluru, Martine Croset, et al.
Chemotherapy|June 10, 2024
Concurrent Use of Abemaciclib and Radiotherapy in Metastatic Breast Cancer Patients: A Single-Center ExperienceEdy Ippolito, Francesco Pantano, Sonia Silipigni, et al.
Expert Opinion on Biological Therapy|August 25, 2020
Denosumab for cancer-related bone lossEmanuela Dell'Aquila, Grazia Armento, Michele Iuliani, et al.
Critical Reviews in Oncology/Hematology|August 5, 2019
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trialsDaniele Santini, Antonio Galvano, Francesco Pantano, et al.
Cancer Biology & Therapy|June 14, 2013
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatmentFrancesco Pantano, Francesco Maria Guida, Caterina Vivaldi, et al.
Tumori|November 6, 2020
Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinomaRaffaele Ratta, Elena Verzoni, Alessia Mennitto, et al.
Hormones (Athens, Greece)|August 8, 2018
A novel germline mutation at exon 10 of MEN1 gene: a clinical survey and positive genotype-phenotype analysis of a MEN1 Italian family, including monozygotic twinsAndrea Palermo, Ettore Capoluongo, Rossella Del Toro, et al.
International Journal of Molecular Sciences|August 12, 2023
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate CancerMaria Concetta Cursano, Emilio Francesco Giunta, Emanuela Scarpi, et al.
Pageof 13